Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of APOL1-mediated kidney disease
Economic impact of diagnostic testing
9 evidence topics · 10 sources
Genetic testing requirement for diagnosis
Manufacturer-sponsored no-cost APOL1 genotyping: Labcorp program
Manufacturer-sponsored no-cost APOL1 genotyping: Natera program
Manufacturer-sponsored no-cost APOL1 genotyping and genetic counseling: Arkana Laboratories program
Billing code for a commercial APOL1 genotyping test
List price or Medicare payment rate for APOL1 genotyping
No evidence found.
Cost of APOL1 genotyping of potential living kidney donors at one US center
“Since May 2017, all potential AA living kidney donors at our center underwent APOL1 genotyping early in the donor evaluation process.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One out of 26 potential donors had high-risk genotype and was therefore declined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A crude cost analysis utilizing our sample suggested probable cost-effectiveness of APOL1 genotyping as it can prevent earlier onset of chronic kidney disease in AA donors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost as a barrier to genetic testing
“Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When offering genetic testing, physicians should counsel patients on risks and potential implications of testing, which may include out-of-pocket expenses, data privacy concerns, emotional distress, and the impact of a positive test result on life and disability insurance applications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost considerations for population, pediatric, and donor APOL1 testing
“At population levels, evaluation of costs and potential benefits is important prior to investing in APOL1 testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet unnecessary testing would be costly and potentially anxiety-provoking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Equipment costs of current APOL1 genotyping methods
“Current available genotyping methods rely on PCR and sequencing and are associated with high equipment costs, long turnaround times and bioinformatic data analysis, all of which can challenge their application in resource-limited settings or at the point-of-care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although APOL1 genotyping is typically performed using quantitative polymerase chain reaction or sequencing, these techniques require specialized technical expertise and costly equipment, resources that are often limited in sub-Saharan Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote